Virtual Alanine Scan of the Main Protease Active Site in Severe Acute Respiratory Syndrome Coronavirus 2
Recently, inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) have been proposed as potential therapeutic agents for COVID-19. Studying effects of amino acid mutations in the conformation of drug targets is necessary for anticipating drug resistance. I...
Main Authors: | Tomoki Nakayoshi, Koichi Kato, Eiji Kurimoto, Akifumi Oda |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/18/9837 |
Similar Items
-
In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors
by: Arun Bahadur Gurung, et al.
Published: (2020-10-01) -
The coronavirus disease 2019 main protease inhibitor from Andrographis paniculata (Burm.f) Ness
by: Sukardiman, et al.
Published: (2020-01-01) -
In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection
by: Annamaria Martorana, et al.
Published: (2020-07-01) -
Identification of Host Cellular Protein Substrates of SARS-COV-2 Main Protease
by: Márió Miczi, et al.
Published: (2020-12-01) -
3C-like protease inhibitors against coronaviruses
by: Perera, Krishani
Published: (2018)